Gary Fanger
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$25.9MFederal grants as PI30 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
30 awards · $25.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 16, 2026 | NIH | SBIR Phase II Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors | $740K | Rise Therapeutics, LLC |
| Jul 28, 2026 | NIH | SBIR Phase II A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis | $968K | Rise Therapeutics, LLC |
| Aug 5, 2025 | NIH | SBIR Phase II A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis | $953K | Rise Therapeutics, LLC |
| Jul 26, 2024 | NIH | SBIR Phase II A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis | $915K | Rise Therapeutics, LLC |
| Jun 26, 2024 | NIH | SBIR Phase II A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy | $171K | Rise Therapeutics, LLC |
| Jun 6, 2024 | NIH | SBIR Phase II A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis | $987K | Rise Therapeutics, LLC |
| Sep 4, 2023 | NIH | SBIR Phase II A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis | $494K | Rise Therapeutics, LLC |
| Jul 26, 2023 | NIH | SBIR Phase II A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis | $1.0M | Rise Therapeutics, LLC |
| Jun 2, 2023 | NIH | SBIR Phase II A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy | $828K | Rise Therapeutics, LLC |
| Jan 10, 2023 | NIH | SBIR Phase II A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis | $923K | Rise Therapeutics, LLC |
| Jul 4, 2022 | NIH | SBIR Phase II A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis | $361K | Rise Therapeutics, LLC |
| Jul 1, 2022 | NIH | SBIR Phase II A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy | $1.0M | Rise Therapeutics, LLC |
| Jun 3, 2022 | NIH | SBIR Phase II A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection | $973K | Rise Therapeutics, LLC |
| Apr 6, 2022 | NIH | SBIR Phase II A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease | $30K | Rise Therapeutics, LLC |
| Apr 5, 2022 | NIH | SBIR Phase II A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease | $459K | Rise Therapeutics, LLC |
| Feb 7, 2022 | NIH | SBIR Phase II A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease | $25K | Rise Therapeutics, LLC |
| Jan 10, 2022 | NIH | SBIR Phase II A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis | $1.0M | Rise Therapeutics, LLC |
| Jun 29, 2021 | NIH | SBIR Phase II A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection | $914K | Rise Therapeutics, LLC |
| May 12, 2021 | NIH | SBIR Phase II A Novel Probiotic for the Treatment of Sjogren's Syndrome | $2.9M | Rise Therapeutics, LLC |
| Apr 1, 2021 | NIH | SBIR Phase I A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy | $387K | Rise Therapeutics, LLC |
| Mar 30, 2021 | NIH | SBIR Phase II A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease | $896K | Rise Therapeutics, LLC |
| Feb 22, 2021 | NIH | SBIR Phase II A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis | $1.0M | Rise Therapeutics, LLC |
| Jul 1, 2020 | NIH | SBIR Phase II A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection | $2.8M | Rise Therapeutics, LLC |
| Jun 24, 2020 | NIH | SBIR Phase II A Novel Probiotic for the Treatment of Sjogren's Syndrome | $950K | Rise Therapeutics, LLC |
| May 19, 2020 | NIH | SBIR Phase II A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease | $892K | Rise Therapeutics, LLC |
| Jan 31, 2020 | NIH | SBIR Phase I A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease | $217K | Rise Therapeutics, LLC |
| Jul 10, 2019 | NIH | SBIR Phase II A Novel Probiotic for the Treatment of Sjogren's Syndrome | $1.9M | Rise Therapeutics, LLC |
| Feb 15, 2019 | NIH | SBIR Phase I A Novel Probiotic Engineered for Enhanced Immunological Function for Treating Inflammatory Bowel Disease | $300K | Rise Therapeutics, LLC |
| Jun 27, 2018 | NIH | SBIR Phase I A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease | $480K | Rise Therapeutics, LLC |
| Feb 6, 2018 | NIH | SBIR Phase I A novel Probiotic for Preventing and Treating Clostridium Difficile Pathogenesis | $300K | Rise Therapeutics, LLC |
Peer ranks
Federal funding#2
Awards as PI#5
Patents#273
Companies
- Rise Therapeutics, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.